New Applications, New Use Cases: The Expanding Need for Endpoint Adjudication
Endpoint adjudication is nothing new. Sponsors often turn to endpoint adjudication committees (EACs) for large, complex studies, but they aren’t limited to large trials anymore. In recent years, we’ve seen a growing trend to leverage EACs in new ways. The goal, however, remains the same: to reduce bias and increase accuracy of clinical trials.
In this paper, we will talk about factors to consider when determining the need for an adjudication committee.
WCG is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two segments, Ethical Review and Clinical Trials Solutions (CTS), WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection. For more information, visit www.wcgclinical.com.